We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+1.33%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$166M
AUM Growth
-$5.51M
Cap. Flow
+$4.97M
Cap. Flow %
3%
Top 10 Hldgs %
90.81%
Holding
19
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CLLS
Cellectis
CLLS
+$3.03M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$2.45M

Top Sells

Rank Stock Value
1
ACHV icon
Achieve Life Sciences
ACHV
+$397K
2
DCOY
Decoy Therapeutics
DCOY
+$120K

Sector Composition

Rank Sector Weight
1 Healthcare 88.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHMA
1
DELISTED
Chiasma, Inc. Common Stock
CHMA
$40.7M 24.56%
2,080,595
– –
TARA icon
2
Protara Therapeutics
TARA
$220M
$31.3M 18.88%
50,447
– –
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$24.7M 14.9%
1,301,413
– –
SIEN
4
DELISTED
Sientra, Inc.
SIEN
$13M 7.86%
219,901
– –
CEMP
5
DELISTED
Cempra, Inc.
CEMP
$11.9M 7.21%
383,935
– –
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$11.2M 6.77%
945,757
– –
TBRA
7
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$5.9M 3.56%
589,244
– –
EVAR
8
DELISTED
Lombard Medical, Inc.
EVAR
$4.45M 2.68%
3,473,452
– –
INNL
9
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$4.18M 2.52%
555,555
– –
CLLS
10
Cellectis
CLLS
$277M
$3.1M 1.87%
+100,000
New +$3.03M
ADAP
11
DELISTED
Adaptimmune Therapeutics
ADAP
$3.01M 1.82%
+250,000
New +$2.45M
RGLS
12
DELISTED
Regulus Therapeutics
RGLS
$2.85M 1.72%
2,728
– –
CBAY
13
DELISTED
Cymabay Therapeutics
CBAY
$2.67M 1.61%
1,600,000
– –
DERM
14
DELISTED
Dermira, Inc.
DERM
$2.42M 1.46%
70,000
– –
ANTH
15
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.03M 1.23%
54,749
– –
CCXI
16
DELISTED
ChemoCentryx, Inc.
CCXI
$1.74M 1.05%
215,000
– –
ACHV icon
17
Achieve Life Sciences
ACHV
$659M
$475K 0.29%
180
-94
-34% -$397K
EPRS
18
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$24K 0.01%
7,896
– –
DCOY
19
Decoy Therapeutics
DCOY
$2.19M
– –
0
– -$120K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q4 2015 Portfolio in Review

As of Q4 2015, Abingworth held 19 positions worth $166M, down 3.2% from $171M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Abingworth's Q4 2015 filing shows 2 new and 1 reduced positions. Its largest new stake was Cellectis: 100,000 shares worth $3.1M. The largest sale was Achieve Life Sciences, an estimated $397K.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier.

  • Abingworth's largest Q4 2015 buy was Cellectis: 100,000 shares worth $3.1M.
  • Abingworth's biggest Q4 2015 reduction was Achieve Life Sciences, cutting an estimated $397K.
  • Abingworth's ten largest holdings make up 91% of its $166M portfolio in Q4 2015.
  • Abingworth opened 2 new positions and closed 0 in Q4 2015.
  • Abingworth's portfolio value fell 3.2% quarter-over-quarter to $166M.

Based on Abingworth's 13F filing for Q4 2015, filed 16 Feb 2016.